{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:33:59Z","timestamp":1793324039920,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ad.2024.10.008","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:07:55Z","timestamp":1728504475000},"page":"T55-T67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses"],"prefix":"10.1016","volume":"116","author":[{"given":"D.","family":"Mart\u00edn-Torregrosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mansilla-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.10.008_bib0400","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clindermatol.2006.07.014","article-title":"Lupus erythematosus: systemic and cutaneous manifestations","volume":"24","author":"Rothfield","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2024.10.008_bib0405","doi-asserted-by":"crossref","first-page":"897987","DOI":"10.3389\/fmed.2022.897987","article-title":"The Burden of Living With Cutaneous Lupus Erythematosus","volume":"9","author":"Drenkard","year":"2022","journal-title":"Front Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0410","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.10.008_bib0415","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/1346-8138.17161","article-title":"An update on clinical trials for cutaneous lupus erythematosus","volume":"51","author":"Xie","year":"2024","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0420","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors-distribution and regulation","volume":"90","author":"De Weerd","year":"2012","journal-title":"Immunol Cell Biol."},{"key":"10.1016\/j.ad.2024.10.008_bib0425","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0952-7915(02)00354-0","article-title":"Links between innate and adaptive immunity via type I interferon","volume":"14","author":"Le Bon","year":"2002","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.ad.2024.10.008_bib0430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrrheum.2009.237","article-title":"Type I interferons: crucial participants in disease amplification in autoimmunity","volume":"6","author":"Hall","year":"2010","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0435","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2133.2007.08137.x","article-title":"The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets","volume":"157","author":"Wenzel","year":"2007","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0440","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0445","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2024.10.008_bib0450","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2665-9913(21)00254-X","article-title":"The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease","volume":"4","author":"Cooles","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0455","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0460","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0465","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"MAbs."},{"key":"10.1016\/j.ad.2024.10.008_bib0470","doi-asserted-by":"crossref","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0475","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1107\/S0907444908007877","article-title":"Structural characterization of a human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan","year":"2008","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"key":"10.1016\/j.ad.2024.10.008_bib0480","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.ad.2024.10.008_bib0485","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2013.35","article-title":"Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-\u03b1 receptor antibody","volume":"93","author":"Wang","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.ad.2024.10.008_bib0490","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1093\/rheumatology\/keab176","article-title":"Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus","volume":"60","author":"Chia","year":"2021","journal-title":"Rheumatol Oxf Engl."},{"key":"10.1016\/j.ad.2024.10.008_bib0495","doi-asserted-by":"crossref","first-page":"e000252","DOI":"10.1136\/lupus-2017-000252","article-title":"Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers","volume":"5","author":"Tummala","year":"2018","journal-title":"Lupus Sci Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0500","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S2665-9913(20)30342-8","volume":"3","author":"Bruce","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0505","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2024.10.008_bib0510","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2024.10.008_bib0515","unstructured":"AstraZeneca. A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis. 2024. [accessed 10 Feb 2024]. Available from: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D3466C00001\/"},{"key":"10.1016\/j.ad.2024.10.008_bib0520","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0525","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.3390\/jcm11123449","article-title":"Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach","volume":"11","author":"Pl\u00fc\u00df","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0530","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/ced.15335","article-title":"Anifrolumab for treatment of refractory cutaneous lupus erythematosus","volume":"47","author":"Blum","year":"2022","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0535","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2022.5242","article-title":"Treatment With Anifrolumab for Discoid Lupus Erythematosus","volume":"159","author":"Trentin","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0540","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2023.04.024","article-title":"Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases","volume":"37","author":"Kowalski","year":"2023","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.ad.2024.10.008_bib0545","first-page":"e39553","article-title":"Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.ad.2024.10.008_bib0550","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","article-title":"Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus","volume":"159","author":"Shaw","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0555","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2023.02.044","article-title":"Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus","volume":"89","author":"Chasset","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0560","doi-asserted-by":"crossref","first-page":"e098","DOI":"10.1097\/JW9.0000000000000098","article-title":"Alopecia secondary to severe discoid lupus responding to anifrolumab","volume":"9","author":"Han","year":"2023","journal-title":"Int J Womens Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0565","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0570","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ced\/llad190","article-title":"Improvement in mucosal discoid lupus erythematosus with anifrolumab","volume":"48","author":"Shaw","year":"2023","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0575","doi-asserted-by":"crossref","first-page":"1253279","DOI":"10.3389\/fimmu.2023.1253279","article-title":"Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood","volume":"14","author":"G\u00fcnther","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.ad.2024.10.008_bib0580","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/biomedicines11112904","article-title":"Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature","volume":"11","author":"Paolino","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.ad.2024.10.008_bib0585","doi-asserted-by":"crossref","first-page":"e2338200","DOI":"10.1001\/jamanetworkopen.2023.38200","article-title":"Anifrolumab for Adolescent Discoid Lupus Erythematosus","volume":"6","author":"Shaw","year":"2023","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.ad.2024.10.008_bib0590","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/09612033231210398","article-title":"Steroid-free flare management of a severe cutaneous lupus flare with anifrolumab","volume":"32","author":"Heide","year":"2023","journal-title":"Lupus."},{"key":"10.1016\/j.ad.2024.10.008_bib0595","first-page":"e576","article-title":"Real-life experience of anifrolumab for cutaneous lupus erythematous","volume":"38","author":"Viedma-Mart\u00ednez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.10.008_bib0600","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/lupus-2023-001007","article-title":"Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE","volume":"10","author":"Bao","year":"2023","journal-title":"Lupus Sci Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0605","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdcr.2023.12.002","article-title":"Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab","volume":"44","author":"Gaffney","year":"2023","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.ad.2024.10.008_bib0610","first-page":"368","article-title":"Refractory cutaneous lupus erythematosus successfully treated with anifrolumab: a case series","volume":"63","author":"Mart\u00edn-Torregrosa","year":"2024","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0615","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2022.11.008","article-title":"A case of Rowell syndrome with excellent improvement following anifrolumab","volume":"31","author":"Shope","year":"2022","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.ad.2024.10.008_bib0620","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/rheumatology\/kead553","article-title":"Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus","volume":"63","author":"Maeshima","year":"2024","journal-title":"Rheumatol Oxf Engl."},{"key":"10.1016\/j.ad.2024.10.008_bib0625","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ad.2024.10.008_bib0630","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun."},{"key":"10.1016\/j.ad.2024.10.008_bib0635","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0640","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2023","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.ad.2024.10.008_bib0645","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0650","unstructured":"AstraZeneca. A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Polymyositis. 2024. [consultado 10 Feb 2024]. Disponible en: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D3463C00003\/"},{"key":"10.1016\/j.ad.2024.10.008_bib0655","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2008.03.016","article-title":"Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?","volume":"118","author":"Coelho","year":"2008","journal-title":"Immunol Lett."},{"key":"10.1016\/j.ad.2024.10.008_bib0660","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2024.10.008_bib0665","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2024.10.008_bib0670","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.ad.2024.10.008_bib0675","unstructured":"AstraZeneca. A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis. 2024. [accessed 10 Feb 2024]. Available from: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D3460C00002\/"},{"key":"10.1016\/j.ad.2024.10.008_bib0680","doi-asserted-by":"crossref","first-page":"631329","DOI":"10.3389\/fped.2021.631329","article-title":"Type I Interferonopathies in Children: An Overview","volume":"9","author":"d\u2019Angelo","year":"2021","journal-title":"Front Pediatr."},{"key":"10.1016\/j.ad.2024.10.008_bib0685","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bjd.20707","article-title":"Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak","volume":"185","author":"Frumholtz","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0690","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0695","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A Randomized Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0700","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2024.10.008_bib0705","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/acr.25058","article-title":"Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta-Analysis","volume":"75","author":"Kneeland","year":"2023","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ad.2024.10.008_bib0710","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med."},{"key":"10.1016\/j.ad.2024.10.008_bib0715","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3389\/fimmu.2019.01440","article-title":"Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.ad.2024.10.008_bib0720","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0625.2012.01475.x","article-title":"Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea","volume":"21","author":"Ghoreishi","year":"2012","journal-title":"Exp Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0725","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ad.2024.10.008_bib0730","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0735","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1600-0560.2006.00527.x","article-title":"Type I interferon-associated cytotoxic inflammation in lichen planus","volume":"33","author":"Wenzel","year":"2006","journal-title":"J Cutan Pathol."},{"key":"10.1016\/j.ad.2024.10.008_bib0740","unstructured":"AstraZeneca. A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and\/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and\/or Intolerant to Antimalarial Therapy. 2023. [accessed 10 Feb 2024]. Available from: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D346BC00001\/"},{"key":"10.1016\/j.ad.2024.10.008_bib0745","unstructured":"University Medical Center Groningen. ANIfrolumab Treatment for 24 Weeks in Patients With Primary Sj\u00f6gren's Syndrome - Efficacy and Safety Assessment in a Randomized, Double-blind, Placebo-controlled Phase-IIa Proof-of-concept Trial (ANISE-II). 2022. [accessed 10 Feb 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05383677"},{"key":"10.1016\/j.ad.2024.10.008_bib0750","unstructured":"University Hospital, Bordeaux. Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Double Blind Prospective, Non Comparative Proof of Concept Phase II Study. 2023. [accessed 10 Feb 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05917561"},{"key":"10.1016\/j.ad.2024.10.008_bib0755","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0760","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21645515.2018.1514228","article-title":"Herpes zoster vaccination in systemic lupus erythematosus: the current status","volume":"15","author":"Mok","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"10.1016\/j.ad.2024.10.008_bib0765","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0770","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40262-023-01238-2","article-title":"Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab","volume":"62","author":"Tang","year":"2023","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.ad.2024.10.008_bib0775","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jcph.2055","article-title":"Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus","volume":"62","author":"Almquist","year":"2022","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.ad.2024.10.008_bib0780","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jcph.2054","article-title":"Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus","volume":"62","author":"Chia","year":"2022","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.ad.2024.10.008_bib0785","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archderm.144.2.173","article-title":"The Cutaneous Lupus Erythematosus Disease Area and Severity Index","volume":"144","author":"Bonilla-Martinez","year":"2008","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.ad.2024.10.008_bib0790","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.2010.09799.x","article-title":"Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus","volume":"163","author":"Kuhn","year":"2010","journal-title":"Br J Dermatol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024007658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024007658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:57:51Z","timestamp":1736845071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024007658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0001731024007658"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.008","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.05.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}